The purpose of this study was to develop and evaluate a new formulation of ziprasidone (ZIP) for improved fasted state absorption and sustained drug release. ZIP solid dispersions were produced via spray drying using Soluplus®, an amphiphilic polymer, as the solubility enhancer. Physicochemical analysis proved that ZIP presented at amorphous state in the spray-dried microparticles and the dissolution rate of ZIP from the Soluplus®-ZIP composite microparticles was significantly increased compared with that of the physical mixtures. Commonly used encapsulation materials including Eudragit® RL, Eudragit® S100 and Ethyl Cellulose were incorporated into the solid dispersions to regulate the drug release kinetics. The formulation containing ethyl cellulose provided the most sustained release behaviors. Pharmacokinetic studies in beagle dogs confirmed that there was no significant difference in oral bioavailability of the microparticles under fasted and fed states, and a prolonged Tmax value was simultaneously achieved compared with the commercial ZIP capsules.
This is a preview of subscription content, log in to check access.
Buy single article
Instant access to the full article PDF.
Price includes VAT for USA
Subscribe to journal
Immediate online access to all issues from 2019. Subscription will auto renew annually.
This is the net price. Taxes to be calculated in checkout.
Area under the curve
Scanning electron microscopy
Fourier-transform infrared spectroscopy
High-performance liquid chromatography
Physical mixture of Soluplus® and Ziprasidone (4:1)
Physical mixture of Soluplus®, Ziprasidone and Ethyl Cellulose (6:1:4)
Soluplus®: Ziprasidone = 4:1
Soluplus®: Ziprasidone: Ethyl Cellulose = 6:1:4
Mean residence time
Greenberg WM, Citrome L. Ziprasidone for schizophrenia and bipolar disorder: a review of the clinical trials. CNS Drug Rev. 2007;13(2):137–77. https://doi.org/10.1111/j.1527-3458.2007.00008.x.
Harvey PD, Bowie CR. Ziprasidone: efficacy, tolerability, and emerging data on wide-ranging effectiveness. Expert Opin Pharmacother. 2005;6(2):337–46. https://doi.org/10.1517/146565220.127.116.117.
Patel NC, Keck PE Jr. Ziprasidone: efficacy and safety in patients with bipolar disorder. Expert Rev Neurother. 2006;6(8):1129–38. https://doi.org/10.1586/1473718.104.22.1689.
Zakowiecki D, Cal K, Kaminski K, Adrjanowicz K, Swinder L, Kaminska E, et al. The improvement of the dissolution rate of ziprasidone free base from solid oral formulations. AAPS PharmSciTech. 2015;16(4):922–33. https://doi.org/10.1208/s12249-015-0285-1.
Xue X, Chen G, Xu X, Wang J, Wang J, Ren L. A combined utilization of Plasdone-S630 and HPMCAS-HF in ziprasidone hydrochloride solid dispersion by hot-melt extrusion to enhance the oral bioavailability and no food effect. AAPS PharmSciTech. 2019;20(1):37. https://doi.org/10.1208/s12249-018-1216-8.
Sachs GS, Ice KS, Chappell PB, Schwartz JH, Gurtovaya O, Vanderburg DG, et al. Efficacy and safety of adjunctive oral ziprasidone for acute treatment of depression in patients with bipolar I disorder: a randomized, double-blind, placebo-controlled trial. J Clin Psychiatry. 2011;72(10):1413–22. https://doi.org/10.4088/JCP.09m05934.
Lincoln J, Stewart ME, Preskorn SH. How sequential studies inform drug development: evaluating the effect of food intake on optimal bioavailability of ziprasidone. J Psychiatr Pract. 2010;16(2):103–14.
Gandelman K, Alderman JA, Glue P, Lombardo I, LaBadie RR, Versavel M, et al. The impact of calories and fat content of meals on oral ziprasidone absorption: a randomized, open-label, crossover trial. J Clin Psychiatry. 2009;70(1):58–62.
Hamelin BA, Allard S, Laplante L, Miceli J, Wilner KD, Tremblay J, et al. The effect of timing of a standard meal on the pharmacokinetics and pharmacodynamics of the novel atypical antipsychotic agent ziprasidone. Pharmacotherapy. 1998;18(1):9–15.
Gu CH, Li H, Levons J, Lentz K, Gandhi RB, Raghavan K, et al. Predicting effect of food on extent of drug absorption based on physicochemical properties. Pharm Res. 2007;24(6):1118–30. https://doi.org/10.1007/s11095-007-9236-1.
Perkins DO. Predictors of noncompliance in patients with schizophrenia. J Clin Psychiatry. 2002;63(12):1121–8.
Thombre AG, Shamblin SL, Malhotra BK, Connor AL, Wilding IR, Caldwell WB. Pharmacoscintigraphy studies to assess the feasibility of a controlled release formulation of ziprasidone. J Control Release. 2015;213:10–7. https://doi.org/10.1016/j.jconrel.2015.06.032.
Thombre AG, Shah JC, Sagawa K, Caldwell WB. In vitro and in vivo characterization of amorphous, nanocrystalline, and crystalline ziprasidone formulations. Int J Pharm. 2012;428(1–2):8–17. https://doi.org/10.1016/j.ijpharm.2012.02.004.
Dening TJ, Rao S, Thomas N, Prestidge CA. Silica encapsulated lipid-based drug delivery systems for reducing the fed/fasted variations of ziprasidone in vitro. Eur J Pharm Biopharm. 2016;101:33–42. https://doi.org/10.1016/j.ejpb.2016.01.010.
Thombre AG, Caldwell WB, Friesen DT, McCray SB, Sutton SC. Solid nanocrystalline dispersions of ziprasidone with enhanced bioavailability in the fasted state. Mol Pharm. 2012;9(12):3526–34. https://doi.org/10.1021/mp3003607.
Thombre AG, Herbig SM, Alderman JA. Improved ziprasidone formulations with enhanced bioavailability in the fasted state and a reduced food effect. Pharm Res. 2011;28(12):3159–70. https://doi.org/10.1007/s11095-011-0505-7.
Miao Y, Chen G, Ren L, Ouyang P. Preparation and evaluation of ziprasidone-phospholipid complex from sustained-release pellet formulation with enhanced bioavailability and no food effect. J Pharm Pharmacol. 2016;68(2):185–94.
Miao Y, Chen G, Ren L, Pingkai O. Characterization and evaluation of self-nanoemulsifying sustained-release pellet formulation of ziprasidone with enhanced bioavailability and no food effect. Drug Deliv. 2015;23(7):1.
Miao Y, Chen G, Ren L, Ouyang P. Controlled release of ziprasidone solid dispersion systems from osmotic pump tablets with enhanced bioavailability in the fasted state. Drug Dev Ind Pharm. 2015;41(8):1353.
Yang W, Liu W, Xiao DC, Selomulya C. Micro-encapsulation and stabilization of DHA containing fish oil in protein-based emulsion through mono-disperse droplet spray dryer. J Food Eng. 2016;175:74–84.
Wu WD, Amelia R, Hao N, Selomulya C, Zhao DY, Chiu YL, et al. Assembly of uniform photoluminescent microcomposites using a novel micro-fluidic-jet-spray-dryer. AICHE J. 2011;57(10):2726–37.
Yanfei M, Guoguang C, Lili R, Pingkai O. Controlled release of ziprasidone solid dispersion systems from osmotic pump tablets with enhanced bioavailability in the fasted state. Drug Dev Ind Pharm. 2015;41(8):1353–62. https://doi.org/10.3109/03639045.2014.950273.
Bera H, Boddupalli S, Nayak AK. Mucoadhesive-floating zinc-pectinate-sterculia gum interpenetrating polymer network beads encapsulating ziprasidone HCl. Carbohydr Polym. 2015;131:108–18. https://doi.org/10.1016/j.carbpol.2015.05.042.
Pawar JN, Shete RT, Gangurde AB, Moravkar KK, Javeer SD, Jaiswar DR, et al. Development of amorphous dispersions of artemether with hydrophilic polymers via spray drying: physicochemical and in silico studies. Asian J Pharm Sci. 2016;11(3):385–95.
Rumondor AC, Stanford LA, Taylor LS. Effects of polymer type and storage relative humidity on the kinetics of felodipine crystallization from amorphous solid dispersions. Pharm Res. 2009;26(12):2599–606. https://doi.org/10.1007/s11095-009-9974-3.
Wu WD, Lin SX, Chen XD. Monodisperse droplet formation through a continuous jet break-up using glass nozzles operated with piezoelectric pulsation. AICHE J. 2011;57(6):1386–92.
Wu WD, Patel KC, Rogers S, Chen XD. Monodisperse droplet generators as potential atomizers for spray drying technology. Dry Technol. 2007;25(12):1907–16.
Truong DH, Tran TH, Ramasamy T, Choi JY, Choi HG, Yong CS, et al. Preparation and characterization of solid dispersion using a novel amphiphilic copolymer to enhance dissolution and oral bioavailability of sorafenib. Powder Technol. 2015;283:260–5.
The authors would like to acknowledge financial support from National Natural Science Foundation of China (Grant No. 81503023).
Conflict of Interest
The authors declare that they have no conflict of interest.
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
About this article
Cite this article
Liu, W., Wang, S., Lu, W. et al. Sustained Release Ziprasidone Microparticles Prepared by Spray Drying with Soluplus® and Ethyl Cellulose to Eliminate Food Effect and Enhance Bioavailability. AAPS PharmSciTech 21, 27 (2020). https://doi.org/10.1208/s12249-019-1592-8
- solid dispersion
- spray drying
- food effect
- sustained release